TABLE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies

Name: TABLE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Creator: aacr.figshare.com
Published: 2024-02-12 00:00:00
License: 暂无描述

aacr.figshare.com2024-02-12 更新2025-03-24 收录

下载链接：

https://aacr.figshare.com/articles/dataset/TABLE_2_from_Phase_I_Study_of_mTORC1_2_Inhibitor_Sapanisertib_CB-228_TAK-228_in_Combination_with_Metformin_in_Patients_with_i_mTOR_AKT_PI3K_i_Pathway_Alterations_and_Advanced_Solid_Malignancies/25206406/1

下载链接

链接失效反馈

官方服务：

资源简介：

Tumor response according to RECIST v1.1 (investigator assessment) in response-evaluable patients

肿瘤根据RECIST v1.1（研究者评估）对可评估响应的患者进行疗效反应评估

提供机构：

aacr.figshare.com